clinical trial · NCT04311606
Anti-VEGF Therapy for Acute Thyroid Eye Disease
Thyroid Eye DiseaseSub-tenon injection of saline followed by a sub-tenon injection of afliberceptSub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of afliberceptSub-tenon injection of hyaluronidase (HA) alone
brief summary
The primary objective of this clinical trial is to assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed by the incidence and severity of adverse events from baseline to day 45. Participants will undergo clinical examinations and receive three injections of aflibercept with saline, aflibercept with hyaluronidase, or hyaluronidase.
started
Nov 2, 2020
primary completion
Dec 17, 2024
completion
Dec 17, 2024
last updated
Dec 31, 2025
official title
Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol